Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Operating Grant: Leadership Award for Vaccine Research - NRC-CIHR

Ottawa Hospital Research Institute

$300,000.00

A Scalable, Small Molecule Enhanced High-Yield Suspension Vero Platform for VSV-Vectored Vaccine Yield to Strengthen Epidemic and Biodefence Preparedness

EF 2025-26

Résumé
Vaccines based on vesicular stomatitis virus (VSV) have proven effective against deadly infections such as Ebola and represent a rapid-response platform for emerging diseases and potential biological threats. However, a major challenge remains: producing enough vaccine quickly and reliably during an outbreak or biodefence emergency. Current manufacturing methods can limit how much vaccine virus is produced, slowing response times and increasing costs. Strengthening Canada's ability to rapidly manufacture vaccines is therefore essential for epidemic preparedness and biodefence. This project aims to increase the yield of VSV-based vaccines-by 10-fold or more-using an innovative combination of biochemistry, bioprocess engineering, and artificial intelligence. We will build on a newly developed suspension version of Vero cells, a cell type widely used for vaccine manufacturing. Unlike traditional methods that require cells to grow attached to surfaces, suspension Vero cells grow freely in liquid, making production easier to scale up in bioreactors. Even in scalable systems, cells contain natural biological "brakes" that limit how efficiently vaccine viruses are produced. Instead of permanently modifying the cells through genetic engineering, we will use carefully selected small molecules that temporarily release these brakes and increase productivity. These compounds act as biochemical tools that make the same cell line more productive, enabling rapid improvements. To identify the best solutions efficiently, we will use carefully planned experiments using advanced statistical methods to test many molecules and combinations in parallel. Artificial intelligence will help prioritize the most promising candidates. We will then confirm performance and translate the approach into scalable bioreactor processes. By increasing yield and scalability, we will reduce timelines and costs while strengthening Canada's capacity for epidemic response and biodefence preparedness.
Programme
Operating Grant: Leadership Award for Vaccine Research - NRC-CIHR
Emplacement
Ontario, Canada
Type de bénéficiaire
Other
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
571356
Name
Diallo Jean-Simon
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Operating Grant: Leadership Award for Vaccine Research
Projecttitle
A Scalable, Small Molecule Enhanced High-Yield Suspension Vero Platform for VSV-Vectored Vaccine Yield to Strengthen Epidemic and Biodefence Preparedness
Programtype2
Operating Grants
Orgnameinp2
Ottawa Hospital Research Institute
Cihramount2
$300,000
Cihrequipment2
$0
Programname2
Operating Grant: Leadership Award for Vaccine Research - NRC-CIHR
Keyworddelim
Ai; Biodefence; Biomanufacturing; Doe; Emergency Preparedness; High-Throughput Screening; Small Molecule; Vaccines; Vero; Vsv
Abstract
Vaccines based on vesicular stomatitis virus (VSV) have proven effective against deadly infections such as Ebola and represent a rapid-response platform for emerging diseases and potential biological threats. However, a major challenge remains: producing enough vaccine quickly and reliably during an outbreak or biodefence emergency. Current manufacturing methods can limit how much vaccine virus is produced, slowing response times and increasing costs. Strengthening Canada's ability to rapidly manufacture vaccines is therefore essential for epidemic preparedness and biodefence. This project aims to increase the yield of VSV-based vaccines-by 10-fold or more-using an innovative combination of biochemistry, bioprocess engineering, and artificial intelligence. We will build on a newly developed suspension version of Vero cells, a cell type widely used for vaccine manufacturing. Unlike traditional methods that require cells to grow attached to surfaces, suspension Vero cells grow freely in liquid, making production easier to scale up in bioreactors. Even in scalable systems, cells contain natural biological "brakes" that limit how efficiently vaccine viruses are produced. Instead of permanently modifying the cells through genetic engineering, we will use carefully selected small molecules that temporarily release these brakes and increase productivity. These compounds act as biochemical tools that make the same cell line more productive, enabling rapid improvements. To identify the best solutions efficiently, we will use carefully planned experiments using advanced statistical methods to test many molecules and combinations in parallel. Artificial intelligence will help prioritize the most promising candidates. We will then confirm performance and translate the approach into scalable bioreactor processes. By increasing yield and scalability, we will reduce timelines and costs while strengthening Canada's capacity for epidemic response and biodefence preparedness.
Competitiondate
202602
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Diallo, Jean-Simon
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $300,000~ $0~